Was the GLP-1 product suitable for Wegovy and Co.?

The story with the egg legends of Wollmilchsau is no longer important: After the onset of diabetes and the reduction of the disease, more and more problems may arise with the group of GLP-1 receptor agonists, which will be the Abnehmspritze pathway . Kidneys and Leber-sollen van solen Präparaten profitable können, the Mittel sollen Herzinfarkte and Schlaganfälle prevent and bei obstruktiver Schlafapnoe halves. A study in which preparation for such diseases and depression helps and can prevent neurodegenerative experiences with Parkinson’s and Alzheimer’s.

The recent publication of the “New England Journal of Medicine” has prompted a comment, which – after a more extensive analysis of the results – is this: We are starting to make a timetable for hormone biology and GLP-1 medicine , the high point has not been used before.

The Einflussreiche Lasker-Stiftung has announced one of the many Research Awards and three Vertreter der GLP-1 Research: Joel Habener from the Massachusetts General Hospital in Boston, Svetlana Mojsov from the Rockefeller University in New York and Lotte Bjerre Knudsen from Pharmakonzern Novo Nordisk in Copenhagen, dem Wegovy-Hersteller. Traditionally, Lasker-Preisträger is considered the highest candidate for the world’s greatest achievement of science: the Nobel Prize.

Lasker-Preisträger: Von der Laborforschung bis zur Zulassung als Arznei

The Australian representatives of the GLP-1 medication of the Grundlagenforschung in his Zulassung: The endocrinologist specializes in the 1970s with hormone, which has become a diabetes type 2 – also Altersdiabetes. If the hormones of Glucagon are removed, it is so that the plan for a few other substances is made: These substances in the poisoned hormone – später GLP-1 (Glucagon-like Peptide-1) are generated – regt the Bauchspeiheldrüse (Pankreas ) one, Insulin is produced and regulated by the Blutzucker level.

Live and live

Der Gesundheit, Wellbeing and the entire Family – jeden zweiten Donnerstag.

The Biochemikerin Mojsov entschlüsselte de Struktur verschiedener GLP-1-Formen. 1992 reported together with Haberer, a davon in humans for the production of insulin sorgt and the blutzucker level sent.

There is a problem with a problem legend: GLP-1 is being deleted on a Blut basis. Knudsen has installed the GLP-1 variants, which last longer in the cooking range. Beim Wirkstoff Liraglutid stieg die Halbwertzeit nach Injektion so von 1.2 auf 13 Stunden. The European Arzneimittelagentur EMA liesß das Präparat 2009 for the tag Einsatz bei Diabetes-Typ-2 zu.

But GLP-1 receptor agonists will no longer target the pancreas, but rather the diet: they will increase appetite and reduce weight. Zur Therapie of overweight would be swimming in the United States in 2014 in Europe for a year.

If the Wirkstoff Semaglutid de Halbwertzeit sogar bei 165 Stunden: A Injektion pro Woche rears the Weight Verlust on an etwa 15 Prozent. The study started in the US in 2017 due to diabetes and in 2021 the weight has increased when we weigh. Inzwieren is the Wirkstoff dort for Erwachsene with Herz-Kreislauf-Erkrankungen and strongly overweight for the prevention of Herzinfarkt and Schlaganfall-zugelassen. It has been a while since there has been some kind of Dutzend GLP-1 Rezeptor Agonists on the market.

“Der Durchbruch kam in Jahr 2016”, said Michael Nauck from the Ruhr-Universität Bochum, a pioneer of the GLP-1 Research. “Damals hat man notices that this Präparate Herz-Kreislauf-Ereignisse wie Herzinfarkt and Schlaganfall could prevent. It is a matter of others with diabetes, one of the best ways to heal. “Such nähmen überweightige Menschen durch solche Präparate in onem solchen Ausmaß ab, “that is no two-way, that is healthy davon profitieren”, concrete of Diabetologie.

“Blockbuster medicine with beispielloser Reichweite”

Zur Begründung für die Auswahl der Preisträger hieß es von der Lasker Foundation: “While my long-term and committed Ausdauer haben Habener, Mojsov and Knudsen changes those healthy Aussichten for your enormous Anzahl of Menschen, his übermäßiges weight ihr Wohlbefinden right.” Ihre Research has “ a Reihe neuer Blockbuster-Medikamente“ ermöglicht, „with beispielloser Reichweite“.

A government refuser still cannot say: In September in “NEJM” a study was done, which included Liraglutid on children in the age range of 6 to 12 years at Abnehmen. Bisher ist das Mittel – ebenso wie Semaglutid – voor Menschen ab 12 Jahren zuglassen.

Because GLP-1 receptor agonists may prevent neurodegenerative diseases that help Parkinson’s or Alzheimer’s, US-Forschende reports in an overview in the Fachblatt “Pharmacological Research” at the end of 2022. Because all neurodegenerative processes play out in one of the most important roles, writes the team of Katherine Kopp from the National Institute on Aging in Baltimore.

Research into Parkinson’s and Alzheimer’s

The GLP-1 protocol of the Fortschreiten of Parkinson’s symptoms in the Frühstadium was able to send a message about a Forschungsteam in April after a smaller study of 160 people in “NEJM”. There were all kinds of things that made it all so high that the war continued for a year, a further Schlüsse could be seen. Man brauche Studien von longer Dauer, hieß es.

When Alzheimer’s is performed, a lot of attention is paid to it, we will see the dairy products in the form of an infusion and a possible process in the nerve fibers. “The effect of the nerve function is very plausible and could be expected in laboratories as well as in the past,” said Alzheimer’s expert Stefan Teipel from the German Center for Neurodegenerative Diseases (DZNE) in Rostock. Zudem diabetes type 2 – also alternative diabetes – as a risk for Alzheimer’s.

“There is also a good Gründe dafür, GLP-1-Rezeptor-Agonisten zu test,” says Teipel. It seems that matters are not in the hands of humans. I am gegenteil: First in one of the meta-analyses in “Journal of Alzheimer’s Studies Reports”, effects on the Disease Marker are not visible on cognitive knowledge development. All the things were now becoming smaller studies. “You can’t have a positive impact,” said Teipel.

Gewissheit produced a large amount of research into the pharmaceutical industry in the Novo Nordisk, which won an award in 2026. “These events became significant in the fall,” said Teipel. “Auch dann, wenn sie inen Effekt stale sollten.”

Neither since fell Fragen offen

One of the following: it may be that fragments from the substance class of the treatment – and the long duration of therapy. You can also abschätzen zu können, since the präparate nor nicht lang nuanced in Einsatz.

Nauck verweist darauf, dass velde große Studien will take as few more years as possible. Zwar setzten etwa 5 tot 7 Prozent der Patienten die Mittel wegen Nebenwirkungen wie Übelkeit und Erbrechen wieder ab. There is no question of an imaginary Nebenwirkungen that is not possible.

Another part of the problem is the Wirkdauer. Beispiel Weight reduction: Heavy welding the injections the Pfunde purzeln. If you have hit the Präparat, you can find yourself in the Regel wieder zu. “If a man stands up, man himself is sure to die, woman for her war,” says the Diabetologist Nauck.

Lifestyle Mittel for a slim figure

If the patient is ill, he can no longer use a tube. Some of the time the problem occurs after preparing for treatment is likely to cause more problems. Der Bedarf is enormous – also as a Lifestyle Mittel for a slim figure. So if the SpaceX and Tesla chief Elon Musk have the idea that the Abnehmspritze is going crazy.

“Ein Mangel an Arzneimitteln, the GLP-1-Rezeptor-Agonisten Enthalten, affects the EU-Mitglied States since 2022 and will be visible until 2024,” writes the Federal Institute for Arzneimittel and Medizinprodukte (BfArM) on the website. The reason for the packaging is also one of the highest quality products after the purchase – also because of “Off-Label-Verwendung zur kosmetischen Wetsabnahme”.

RND/dpa